Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
Authors:
- 27 November 2025
- journal article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 11 (2) , 124-136
Abstract
No abstract availableKeywords
Funding Information
- Fudan University (2020ZSLC06)
- Zhongshan Hospital
This publication has 33 references indexed in Scilit:
- The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgeryCancer, 2022
- Integrating cytotoxic, targeted and immune therapies for cholangiocarcinomaJournal of Hepatology, 2022
- Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic targetJournal of Hepatology, 2022
- Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinomaJournal of Hepatology, 2022
- Biliary tract cancerThe Lancet, 2021
- The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancyHPB, 2020
- Liver resection and transplantation for intrahepatic cholangiocarcinomaJournal of Hepatology, 2020
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBritish Journal of Surgery, 2018
- High expression of Dickkopf‐related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgeryCancer, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009